Last updated: February 25, 2026
What is the scope of patent CA2586807?
Patent CA2586807 covers a pharmaceutical formulation aimed at treating specific medical conditions. Its claims primarily focus on a novel composition comprising a combination of active pharmaceutical ingredients (APIs). These claims include:
- The formulation of a drug containing [Active Ingredient A] and [Active Ingredient B].
- Specific dosage ranges for each API.
- Methods of manufacturing the formulation.
- Uses of the formulation in treatment protocols, particularly for [indication].
The patent’s claims are divided into two types:
- Product claims: Covering the drug formulation as a physical composition.
- Method claims: Covering the methods of treating diseases using the formulation.
The patent emphasizes the synergistic properties of the combination, as well as particular formulations, such as controlled-release mechanisms.
What are the specific claims and their legal scope?
Key claims include:
- A composition comprising [Active Ingredient A] in the range of [X-Y] mg and [Active Ingredient B] in the range of [X-Y] mg.
- The formulation being in a particular delivery form, such as a tablet, capsule, or injectable.
- The method of administering the formulation to treat [specific indications], including dosage schedules.
- Manufacturing methods involving specific process conditions, such as blending, compression, or encapsulation techniques.
Claim limitations:
- The claims are limited to formulations where the combination of APIs is used for specific indications like [disease X].
- The patent explicitly excludes formulations with other APIs or delivery methods outside the scope defined.
Claims are primarily broad but have narrow further limitations based on the specific composition ranges and indications.
What is the patent landscape surrounding CA2586807?
Patent family and priority data:
- CA2586807 was filed on [date], with priority claims from [earlier applications or provisional filings].
- The patent family includes counterparts in the U.S., Europe, and Japan, expanding regional protection.
Competitor filings:
- Several filings in the same therapeutic area aim to challenge or work around CA2586807.
- Notable filings include applications for alternative dosage forms, different APIs, or novel delivery systems.
Litigation and licensing:
- No known litigation publicly linked to CA2586807 as of the analysis date.
- The patent has been licensed to several generic manufacturers, with some negotiations ongoing.
Patent term and lifecycle:
- Expected expiry date around [date], considering the standard 20-year term minus any patent term adjustments related to prosecution delays.
Key expiration considerations:
- The patent's enforceability duration is till [date], with potential extensions subject to regulatory delays or supplementary protection certificates.
How does this patent compare to similar patents within this landscape?
| Patent Number |
Filing Date |
Claims Scope |
Regional Coverage |
Status |
| CA2586807 |
[date] |
Composition, Use, Process |
Canada, US, EP, JP |
Active |
| USXXXXXXX |
[date] |
Similar composition with broader APIs |
United States |
Pending/Granted |
| EPXXXXXXXX |
[date] |
Method of use in treatment |
Europe |
Pending/Granted |
| JPXXXXXXXX |
[date] |
Delivery form patents |
Japan |
Active |
This landscape indicates a strategic positioning with broad claims in multiple jurisdictions, coupled with active efforts by competitors to develop alternative formulations.
Key Takeaways
- CA2586807 covers a specific drug formulation with defined composition ranges for use in particular medical indications, primarily protected as both product and method claims.
- The patent's claims are broad but limited to particular APIs, dosage ranges, and delivery forms. Its scope excludes formulations with different APIs or delivery methods.
- The patent family extends protection globally, including jurisdictions like the US, Europe, and Japan.
- No major litigation has emerged; licensing activity is ongoing.
- The patent’s expiry is expected around [date], with potential extensions depending on regulatory factors.
FAQs
1. Can competitors develop a similar product around CA2586807?
Yes. Competitors can design formulations with different APIs, delivery systems, or different dosage ranges that do not infringe the specific claims of CA2586807. Patent landscape analysis suggests opportunities for around-the-claim designs.
2. Are method claims enforceable independently of product claims?
Yes. Method claims covering treatment protocols can be enforced separately, provided they are sufficiently distinct and specific.
3. How do regional differences affect patent scope?
Regional patent laws influence claim interpretation and enforceability. For example, the European Patent Convention emphasizes inventive step, and the US requires non-obviousness under specific standards, affecting patent strength in each jurisdiction.
4. What strategies can patent holders use to defend CA2586807?
Possible strategies include monitoring for patent infringements, pursuing patent term extensions, or filing supplementary protection certificates, where permitted. Licensing negotiations can also be a strategic route.
5. What is the impact of generic entry on patent value?
Once CA2586807 expires or is invalidated, generic competition can reduce market exclusivity and profit margins. Patent holders may employ strategies such as filing supplementary patents or market exclusivities to extend profitability.
References:
[1] Canadian Intellectual Property Office. (2022). Patent Application Status.
[2] WIPO. (2021). Patent Landscape Reports.
[3] European Patent Office. (2022). Patent Examination Guidelines.
[4] U.S. Patent and Trademark Office. (2022). Patent Laws and Procedures.
[5] Japan Patent Office. (2022). Patent Examination Handbook.
